VC firms
LYZZ Capital is a leading global healthcare-dedicated VC/PE firm. We currently are actively investing out of USD and RMB funds totaling over USD$460 million. The LYZZ team is composed of highly experienced investment and operating professionals from leading pharmaceutical/biotech companies and Wall Street firms with strong scientific and medical professionals background. We’ve worked together for over a decade and have cultivated a cordial, flat and team-oriented working environment. Our team’s biotech investment experience extends back over 15 years, with more 10 years of presence in China alone. We invest in talents, assets and technologies globally, with an emphasis on unmet medical needs and large market potential in China.
Overview
Location
China, Shanghai
Employees
11-50
Founded date
2014
Investment Type
Venture Capital
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 12, 2021 | Baird Capital Invests in Jumpcode Genomics | Baird Capital announced today that its venture team has completed an investment in Jumpcode Genomics ("Jumpcode"), a genome technology company focused on improving the understanding of human disease. Joining Baird Capital in the $... |
Reviews 0
FAQ about LYZZ Capital
When was LYZZ Capital founded?
LYZZ Capital was founded in 2014.
What has the press written about LYZZ Capital?
Parsers VC has collected 2 articles mentioning LYZZ Capital, among them “Baird Capital Invests in Jumpcode Genomics” (Jan 12, 2021).
Is LYZZ Capital still active?
Yes, LYZZ Capital is active; its latest activity on Parsers VC dates from Jan 12, 2021.